News

Stay current with the latest news and events from TriSalus

2021

TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors

The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences®, an emerging immuno-oncology company committed to transforming outcomes for patients with liver and pancreatic tumors, today announced a strategic research collaboration to evaluate the treatment of tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition immunotherapy.

read more

TriSalus Life Sciences Receives Expanded Reimbursement Authorization from CMS for TriNav Infusion System

TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors, today announced that the Centers for Medicare & Medicaid Services (CMS) has expanded authorization for transitional pass-through (TPT) payment for its TriNav™ Infusion System. The device may now be used with the procedure code (37242) for vascular embolization or occlusion in the artery, which is commonly used for pre-treatment mapping in Y-90 procedures.[i] This is in addition to the previously approved use of procedure code (37243) for vascular embolization or occlusion in organs.[ii] The January 1, 2021 clarification confirms CMS will make transitional pass-through (TPT) payment when either code is appropriately reported in association with TriNav and TPT HCPCS Code C1982.

read more

2020

TriSalus Life Sciences Appoints Trevor McCaw as Chief Commercial Officer

TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors, announced today the appointment of Trevor McCaw as Chief Commercial Officer, a new position within TriSalus reporting directly to TriSalus CEO, Mary Szela. McCaw will play a central role in integrating the Company’s therapeutics and innovative drug delivery systems to provide a total solution for patients. McCaw was most recently President and Chief Commercial Officer of Clerio Vision.

read more

TriSalus Life Sciences Appoints Steven Katz, M.D., Chief Medical Officer

TriSalus Life Sciences (TriSalus), an emerging immuno-oncology Company committed to transforming outcomes for patients with solid tumors, announced today the appointment of Steven Katz, M.D., as its Chief Medical Officer. Katz will oversee the Company’s clinical development strategy as it seeks to overcome poor outcomes in the treatment of solid tumors by combining TriSalus’ proprietary, FDA-cleared intravascular, regional drug delivery technology with immuno-oncology therapeutics. Katz has served as the Company’s Chief Medical Advisor and as Chairman of its Scientific Advisory Board since 2018.

read more

TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for liver and pancreatic tumors, today announced that they have entered into an asset purchase agreement under which TriSalus has purchased SD-101, a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide, which has been studied in advanced cutaneous melanoma, and is currently in clinical trials for high risk Stage II/III breast cancer. Purchased assets include SD-101-related Intellectual Property, clinical data, regulatory filings, and inventory.

read more

TriSalus Appoints Rajesh B. Mistry Chief Financial Officer

TriSalus Life Sciences (“TriSalus”), a company committed to transforming outcomes for patients with solid tumors, today announced the appointment of Rajesh B. Mistry as Chief Financial Officer. Mr. Mistry joins TriSalus with a wide spectrum of healthcare experience, spanning pharmaceuticals, biotech, medical devices, and healthcare services. His background extends from VC-backed start-ups to publicly traded, multinational corporations where he drove M&A, corporate finance and capital raising efforts.

read more

TriSalus Life Sciences Launches the New TriNav™ Infusion System, an Innovative Solution Designed to Overcome Infusion Barriers Within Solid Tumors

TriSalus™ Life Sciences (“TriSalus”), a company committed to transforming outcomes for patients with solid tumors, today announced the launch of its TriNav™ Infusion System (“TriNav”). Powered by its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach with SmartValve™ technology, TriNav is designed to help overcome the infusion barriers that limit therapeutic uptake in solid tumors, including hepatocellular carcinoma (HCC) and liver metastases.

read more

2019

TriSalus Life Sciences’ Surefire® Spark™ Infusion System (TriNav™) Receives CMS Approval for Transitional Pass-Through Payment Status Designed to Improve Therapeutic Distribution and Penetration in Solid Tumors

TriSalus™ Life Sciences (formerly Surefire Medical Inc.), a company committed to treating cancer at its origins, today announced that the Centers for Medicare & Medicaid Services (CMS) granted approval for transitional pass-through (TPT) payment for its Surefire® Spark™ Infusion System.

read more

TriSalus Appoints Two New Members to Its Board of Directors

TriSalus™ Life Sciences announced the election of Diane Parks and Yongxin Han to its Board of Directors, effective immediately.
The appointment of two new members of the company’s board of directors further advances the transformation into an oncology platform and brings expertise in the development and commercialization of drug and drug delivery technology.

read more